Pulmonx Corporation provided revenue guidance for the third quarter ended September 30, 2023. The company's total worldwide revenue for the third quarter of 2023 is anticipated to be approximately $17.6 million, representing growth of approximately 30% over the same quarter last year.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.14 USD | +1.49% |
|
+4.16% | -51.84% |
06-24 | Pulmonx Corporation(NasdaqGS:LUNG) dropped from S&P Healthcare Equipment Select Industry Index | CI |
06-04 | Lake Street Initiates Pulmonx With Buy Rating, $12 Price Target | MT |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-51.84% | 238M | |
+75.69% | 12.57B | |
+12.50% | 7B | |
-30.50% | 6.78B | |
+9.11% | 5.2B | |
-20.06% | 4.67B | |
+19.81% | 4.26B | |
-21.04% | 3.84B | |
-28.39% | 2.7B | |
-1.73% | 1.98B |
- Stock Market
- Equities
- LUNG Stock
- News Pulmonx Corporation
- Pulmonx Corporation Provides Revenue Guidance for the Third Quarter Ended September 30, 2023